A6X.F AXICHEM AB A
- Market cap
- EUR 7.86M
- P/E
- -
- P/B
- 1.56x
- ROE
- -25.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is A6X.F undervalued?
Graham numberThe Graham number of AXICHEM AB A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AXICHEM AB A fundamental analysis
No fundamental analysis for AXICHEM AB A yet.
AXICHEM AB A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AXICHEM AB A
aXichem AB (publ), a biotechnology company, engages in the development of natural analogue ingredients in Sweden. The company offers aXivite, a natural analogue capsaicin solution for a range of dietary health applications; aXiphen-bio, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; and aXiphen, a solution for improved heal…
Full company profileAXICHEM AB A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AXICHEM AB A annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 4.36M | 5.01M | 1.81M | 8.57M | 18.4M | 15.7M |
| Gross Profit | 909K | 3.82M | 1.41M | 7.08M | 9.08M | 9.84M |
| Operating Income | -15.1M | -14.5M | -17.3M | -15.8M | -17.5M | -14.2M |
| EBITDA | - | -11.0M | -13.5M | -11.6M | -12.6M | -9.17M |
| Net Income | -15.1M | -17.3M | -20.8M | -17.8M | -17.6M | -14.3M |
| EPS | -0.88 | -1.00 | -0.93 | -0.30 | -0.30 | -0.21 |
| Balance Sheet | ||||||
| Total Assets | 58.8M | 61.3M | 61.5M | 74.3M | 61.1M | 59.5M |
| Total Liabilities | 2.47M | 20.9M | 13.0M | 4.13M | 8.22M | 4.19M |
| Shareholders' Equity | 56.3M | 40.3M | 48.5M | 70.1M | 52.9M | 55.2M |
| Cash & Short-term Investments | 9.45M | 6.55M | 4.31M | 14.4M | 3.08M | 2.87M |
| Cash Flow | ||||||
| Operating Cash Flow | -15.6M | -19.1M | -15.7M | -11.5M | -11.3M | -8.13M |
| Capital Expenditure | 4.73M | 2.61M | 5.10M | 6.50M | 4.66M | 0.00 |
| Free Cash Flow | -20.3M | -21.7M | -20.8M | -18.0M | -16.0M | -8.13M |
| Ratios | ||||||
| ROE | -26.8% | -42.8% | -42.9% | -25.4% | -33.4% | -25.9% |
| ROA | -25.7% | -28.2% | -33.8% | -24.0% | -28.9% | -24.1% |
| Net Profit Margin | -346.0% | -344.7% | -1,150.4% | -207.9% | -95.6% | -91.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
AXICHEM AB A dividends
AXICHEM AB A has not paid dividends in the last 7 fiscal years.
Who owns AXICHEM AB A
- Insiders 15.47%
- Institutions 34.86%
- Public & others 49.67%
- Shares outstanding 67.7M
- Free float 48.4M
AXICHEM AB A company profile
- Company name
- AXICHEM AB A
- Ticker
- A6X.F
- ISIN
- SE0005250719
- Exchange
- Frankfurt Exchange
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 7
- Fiscal year end
- December
- Address
- SOedergatan 26, Malmö, Sweden, 211 34
- Phone
- 46 40 12 13 55
- Website
- axichem.com
About AXICHEM AB A
aXichem AB (publ), a biotechnology company, engages in the development of natural analogue ingredients in Sweden. The company offers aXivite, a natural analogue capsaicin solution for a range of dietary health applications; aXiphen-bio, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; and aXiphen, a solution for improved health for chickens, hens, pigs, and piglets. The company was founded in 1999 and is based in Malmö, Sweden.
AXICHEM AB A management
4- Mr. Torsten HelsingCEO & Director · born 1957
- Mr. Erik LagerChief Operations Officer · born 1975
- Ms. Gunilla SavringChief Investor Relations Officer · born 1962
- Mr. Lucas AltepostVP and Chief Sales & Marketing officer · born 1967